[1] Gillespie SW, et al. Islatravir: evaluation of clinical development for HIV and HBV. Expert Opin Investig Drugs. 2024 Feb;33(2):85-93. DOI:
10.1080/13543784.2024.2305130[2] Liu AY, et al. CROI 2024: Global Epidemiology and Prevention of HIV and Other Sexually Transmitted Diseases. Top Antivir Med. 2024 Jul 17;32(3):447-482. PMID:39142289
[3] Gunaratne SH, et al. CROI 2024: The Challenges of Sustained Viral Suppression, Advanced HIV Disease, and Ending the HIV Epidemic Targets. Top Antivir Med. 2024 Aug 12;32(4):542-567. PMID:39746674
[4] Zhernov YV, et al. Microbicides for Topical HIV Immunoprophylaxis: Current Status and Future Prospects. Pharmaceuticals (Basel). 2024 May 22;17(6):668. DOI:
10.3390/ph17060668